












































































In stage 1, we conducted a mega-analysis combining genome-wide 
assocation study (GWAS) data from 17 separate studies (with a total of 
9,394 cases and 12,462 controls; Table 1 and Supplementary Tables 1,2). 
We imputed allelic dosages for 1,252,901 autosomal SNPs (Table 1, 
Supplementary Table 3 and Supplementary Note) using HapMap3 
as the reference panel1. We tested for association using logistic regres-
sion of imputed dosages with sample identifiers and three principal 
components as covariates to minimize inflation in significance test-
ing caused by population stratification. The quantile-quantile plot 
(Supplementary Fig. 1) deviated from the null distribution with a 
population stratification inflation factor of λ = 1.23. However, λ1000, 
a metric that standardizes the degree of inflation by sample size, was 
only 1.02, similar to that observed in other GWAS meta-analyses2,3. 
This deviation persisted despite comprehensive quality control and 
inclusion of up to 20 principal components (Supplementary Fig. 1). 
Thus, we interpret this deviation as indicative of a large number of 
weakly associated SNPs consistent with polygenic inheritance4. We 
also examined 298 ancestry-informative markers (AIMs) that reflect 
European-ancestry population substructure5. Unadjusted analyses 
showed greater inflation in the test statistics than we saw for all mark-
ers (AIMs λ = 2.26 compared to all markers λ = 1.56). After inclusion 
of principal components, the distributions of the test statistics did not 
differ between AIMs (λ = 1.18) and all markers (λ = 1.23), a result 
inconsistent with population stratification explaining the residual 
deviation seen in Supplementary Figure 1. Moreover, the results of 
a meta-analysis using summary results generated using study specific 
principal components (Supplementary Note) were highly correlated 
with those from the mega-analysis (Pearson correlation = 0.94, with a 
similar λ = 1.20; Supplementary Fig. 2). Of the ten SNPs in Table 2, 
four increased and six decreased in significance, suggesting that the 
most extreme values did not result from systematic inflation artifacts. 
Therefore, our primary analysis used unadjusted P values (neverthe-
less, see Table 2 for stage 1 P values adjusted for λ (ref. 6).
In stage 1 (Table 2, Supplementary Table 4 and Supplementary 
Figs. 3 and 4), 136 associations reached genome-wide significance 
(P < 5 × 10−8)7. The majority of these associations (N = 129) mapped 
to 5.5 Mb in the extended major histocompatibility complex (MHC, 
6p21.32-p22.1), a region of high linkage disequilibrium (LD) previ-
ously implicated in schizophrenia in a subset of the samples used 
here4,8,9. The other stage 1 regions included new regions (10q24.33 
and 8q21.3) and previously reported regions (18q21.2 at TCF4 (encod-
ing transcription factor 4) and 11q24.2 (ref. 8)). The signal at 11q24.2 
is ~0.85 Mb from NRGN (encoding neurogranin) and is uncorrelated 
with the previously associated variant near this gene8.
In Table 2 and Supplementary Table 4, we denote regions of associ-
ation by the most significant marker. Associated SNPs with r2 ≥ 0.2 in 
HapMap3 (CEU+TSI populations) were not considered independent. 
However, we noticed instances where multiple SNPs within 250 kb of 
each other yielded evidence for association (P < 10−5) despite weak 
LD (r2 < 0.2) between them. For regions with P < 10−6, we performed 
a conditional analysis using as covariates the dosages of the strong-
est associated SNP, principal components 1–4 and 6 and study indi-
cator. We observed multiple statistically independent signals at the 
MHC. Although a number of SNPs within the MHC were poten-
tially independent per HapMap r2 values, only rs9272105 withstood 
formal conditional analysis, showing P = 1.8 × 10−6 conditional on 
association to the best SNP, rs2021722 (stage 1 P = 4.3 × 10−11, inter-
SNP distance = 2.4 Mb, r2 = 0.01 in HapMap). Excluding the MHC 
region, we identified six regions with at least one SNP associated at 
P < 10−5 and a second SNP with a conditionally independent P < 10−3 
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(Supplementary Table 5). We performed 100 simulations after per-
muting case-control status randomly within each study. In contrast 
to the six regions in the real dataset, we never observed more than 
a single region with co-localized statistically independent signals in 
any simulated genome-wide scan, indicating our observation is highly 
unlikely to have occurred by chance.
Noteworthy co-localizing independent signals occurred at three 
regions (Supplementary Table 5): one region with a genome-wide 
significant association at 10q24.32-q24.33 (Table 2), a second region 
that nearly met this threshold at MAD1L1 (encoding mitotic arrest 
deficient-like 1; rs10226475, P = 5.06 × 10−8; Supplementary Table 4) 
and a third region at CACNA1C (encoding calcium channel, voltage-
dependent, L type, α 1C subunit), the latter of which has previously 
been associated with bipolar disorder10 and other psychiatric pheno-
types including schizophrenia11. The conditionally independent signal 
at CACNA1C was more significant than any observation made in 100 
permutations of the entire experiment (both conditional P < 10−5) and 
supports CACNA1C in schizophrenia after genome-wide correction 
(P < 0.01), even without considering these prior reports.
In stage 2, we evaluated in 29,839 independent subjects (8,442 
cases and 21,397 controls) the most significant SNPs (N = 81) in 
each LD region where at least one SNP had surpassed P < 2 × 10−5 
table 1 study design and samples
Collection Country Platform
Cases included by sex Controls included by sex
Male Female Unknown Total Male Female Unknown Total
Cardiff UK UK Affymetrix 500K 320 152 0 472 1,442 1,492 0 2,934
CATIE United States Affymetrix 500K; Perlegen 164K 308 94 0 402 161 46 0 207
ISC-Aberdeen UK Affymetrix 5.0 536 184 0 720 447 251 0 698
ISC-Cardiff Bulgaria Affymetrix 6.0 270 257 0 527 291 318 0 609
ISC-Dublin Ireland Affymetrix 6.0 188 82 0 270 258 602 0 860
ISC-Edinburgh UK Affymetrix 6.0 267 101 0 368 146 138 0 284
ISC-London UK Affymetrix 5.0; Affymetrix 500K 369 149 0 518 207 284 0 491
ISC-Portugal Portugal Affymetrix 5.0 213 133 0 346 80 135 0 215
ISC-SW1 Sweden Affymetrix 5.0 93 75 0 168 82 85 0 167
ISC-SW2 Sweden Affymetrix 6.0 231 159 0 390 116 113 0 229
MGS United States, 
Australia
Affymetrix 6.0 1,863 816 0 2,679 1,140 1,344 0 2,484
SGENE-Bonn Germany Illumina 550K 238 236 0 474 664 640 0 1,304
SGENE-Copenhagen Denmark Illumina Human 610-Quad 280 202 0 482 268 189 0 457
SGENE-Munich Germany Illumina 300K 279 155 0 434 167 184 0 351
SGENE-TOP3 Norway Affymetrix 6.0 132 116 0 248 176 175 0 351
SGENE-UCLA The Netherlands Illumina 550K 529 175 0 704 310 321 – 631
Zucker Hillside United States Affymetrix 500K 128 64 0 192 92 98 0 190
Grand totals for the GWAs 6,244 3,150 0 9,394 6,047 6,415 – 12,462
Multicenter Pedigree Europe, United 
States, Australia
Illumina Human 610-Quad n.a. n.a. 0 583 0 0 0 0
SGENE-Aarhus Denmark Illumina Human 610-Quad 477 399 0 876 477 397 0 874
SGENE-Aarhus Denmark Centaurus 114 102 1 217 176 317 0 493
SGENE-Belgium Belgium Centaurus; Illumina 370K 326 184 0 510 149 192 0 341
SGENE-Copenhagen Denmark Centaurus 264 198 0 462 499 375 0 874
SGENE-Iceland Iceland Illumina 300K 346 185 0 531 5,802 5,813 0 11,615
SGENE-England UK Illumina 300K 71 22 0 93 48 40 0 88
SGENE-Helsinki Finland Illumina 300K 112 70 0 59 122 75 0 147
SGENE-Kuusamo Finland Illumina 300K 123 50
SGENE-Hungary Hungary Centaurus 105 136 0 241 89 125 0 214
SGENE-Italy Italy Illumina 300K 48 36 0 84 50 39 0 89
SGENE-Munich Germany Illumina 300K 280 186 0 163 887 912 0 185
SGENE-Munich Germany Centaurus 303 1,614
SGENE-Russia Russia Centaurus 132 343 0 475 178 290 0 468
SGENE-Sweden Sweden Centaurus 158 94 0 252 178 109 0 287
SW3 Sweden Affymetrix 6.0 327 212 0 539 457 448 0 905
SW4 Sweden Affymetrix 6.0 656 407 0 1,063 605 568 0 1,173
UQ and ASRB Australia SequenomMassArray 347 190 21 558 487 455 15 957
ISGC and WTCCC2 Ireland Affymetrix 6.0 968 342 0 1,310 245 778 0 1,023
Grand totals for the replication follow up 4,731 3,106 22 8,442 10,449 10,933 15 21,397
Stage 1 describes the 17 samples that provided full GWAS genotyping data, and stage 2 describes the 19 studies that provided results for the top SNPs identified in the combined 
analysis of stage 1 studies. Stage 2 replication SGENE-Belgium had four cases missing sex information. Stage 2 replication SGENE-Aarhus (focused genotyping sample) had one 
case missing sex information. Stage 2 replication-University of Queensland had 21 cases and 15 controls missing sex information. Sex information for the two stage 2 replication 
SGENE-Munich samples are combined. Sex information for the two stage 2 replication SGENE-Finnish (Helsinki and Kuusamo) samples are combined to enable that these two 
samples are located adjacent to each other in the table (rather than alphabetically). Multicenter Pedigree was a family sample, and so case sex counts are not applicable (n.a). 
SGENE, Schizophrenia Genetics Consortium; ISC, International Schizophrenia Consortium; TOP3, Thematic Organized Psychoses Research 3; UCLA, University of California at 
Los Angeles; SW1, Sweden 1; SW2, Sweden 2; WTCCC, Wellcome Trust case Control Consortium; for the Multicenter Pedigree study, the number of cases indicates the number of 
families; CATIE, Clinical Antipsychotic Trials of Intervention Effectiveness; MGS, Molecular Genetics of Schizophrenia; UQ, University of Queensland; ASRB, Australian  
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(Supplementary Table 6) in the mega-analysis. Of 22 SNPs from the 
MHC, 5 surpassed the genome-wide significant threshold in stages 1 and 
2 combined (minimum P = 2.2 × 10−12 at rs2021722; Supplementary 
Table 6). Excluding the MHC region, a sign test for consistency between 
stages 1 and 2 was highly significant (P < 10−6), with the same direction 
of effect as observed stage 1 also being observed in stage 2 for 49 of 
59 SNPs. A Fisher’s combined test revealed the distribution of stage 2 
P values was unlikely to have occurred by chance (P < 10−15). We also 
performed a transmission analysis using the family based Multicenter 
Pedigree replication sample in conjunction with a GWAS of 622 parent-
offspring schizophrenia trios from Bulgaria12, and the stage 1 associated 
allele was over-transmitted to cases for 44 of the 59 SNPs (one-sided 
P = 1.0 × 10−4). Thus, the stage 2 replication results are highly consistent 
with the stage 1 discovery results.
In the combined dataset (stages 1 and 2), five new (1p21.3, 2q32.3, 
8p23.2, 8q21.3 and 10q24.32-q24.33) and two previously reported 
(6p21.32-p22.1 and 18q21.2) loci met genome-wide significance 
(Figs. 1,2, Table 2, Supplementary Tables 6,7 and Supplementary 
Fig. 4). After adjusting for λ (ref. 6), four loci (1p21.3, 6p21.32-p22.1, 
10q24.32-q24.33 and 18q21.2) remained significant at P ≤ 5 × 10−8. For 
the primary analyses (unadjusted for λ), the strongest new association 
was at 1p21.3 (rs1625579; P = 1.6 × 10−11), which is over 100 kb from 
any RefSeq protein-coding gene but is within intron 3 of AK094607, 
which contains the primary transcript for MIR137 (ref. 13). The next 
best locus, 10q24.32 (Supplementary Table 5 and Supplementary 
Fig. 5), has independent associations 130 kb apart at rs7914558 (P = 1.8 
× 10−9) and rs11191580 (P = 1.1 × 10−8), implicating a 0.5-Mb region 
containing multiple genes (Supplementary Fig. 5). The third best 
locus, rs7004633 (P = 2.8 × 10−8) on 8q21.3, is 400 kb from the nearest 
gene (MMP16, encoding matrix metallopeptidase 16). The fourth best 
locus, rs10503253 (P = 4.4 × 10−8) at 8p23.2, is in an intron of CSMD1 
(encoding CUB and Sushi multiple domains 1). Finally, rs17662626 
(P = 4.7 × 10−8) at 2q32.3 is intergenic, mapping 300 kb from a non-
coding RNA, PCGEM1 (prostate-specific transcript 1)14.
table 2 top genome-wide association results for schizophrenia
SNP Chr. Mb Alleles Frequency P (GC-adjusted P ) OR (95% CI)
Consistency  
of direction Gene Distance (kb)
5.72 × 10−7 (6.52 × 10−6) 1.14 (1.08–1.19)
rs1625579 1p21.3a 98.3 TG 0.80 2.65 × 10−6 (n.a.) 1.11 (1.07–1.16) +−++++−+ MIR137 Intragenic
1.59 × 10−11 (6.87 × 10−10) 1.12 (1.09–1.16)
3.09 × 10−6 (2.60 × 10−5) 1.22 (1.13–1.30)
rs17662626 2q32.3a 193.7 AG 0.91 1.70 × 10−3 (n.a.) 1.16 (1.06–1.27) + −+ +++ PCGEM1 343
4.65 × 10−8 (1.25 × 10−6) 1.20 (1.13–1.26)
4.30 × 10−11 (2.76 × 10−9) 1.18 (1.13–1.23)
rs2021722 6p21.3-p22.1 30.3 CT 0.78 1.55 × 10−3 (n.a.) 1.10 (1.03–1.17) + ++ −++ TRIM26 Intragenic
2.18 × 10−12 (2.88 × 10−10) 1.15 (1.11–1.19)
3.84 × 10−7 (4.71 × 10−6) 1.14 (1.09–1.19)
rs10503253 8p23.2a 4.2 AC 0.19 7.60 × 10−3 (n.a.) 1.08 (1.01–1.14) + ++ +−+ CSMD1 Intragenic
4.14 × 10−8 (8.98 × 10−7) 1.11 (1.07–1.15)
1.45 × 10−8 (3.22 × 10−7) 1.16 (1.11–1.21)
rs7004633 8q21.3a 89.8 GA 0.18 0.011 (n.a.) 1.05 (1.01–1.10) ++−+++−+ MMP16 421
2.75 × 10−8 (7.03 × 10−7) 1.10 (1.07–1.14)
1.58 × 10−7 (2.27 × 10−6) 1.11 (1.07–1.15)
rs7914558 10q24.32a 104.8 GA 0.59 1.07 × 10−3 (n.a.) 1.08 (1.03–1.13) + ++ +++ CNNM2 Intragenic
1.82 × 10−9 (3.11 × 10−8) 1.10 (1.07–1.13)
2.23 × 10−8 (4.58 × 10−7) 1.22 (1.15–1.29)
rs11191580 10q24.33a 104.9 TC 0.91 5.09 × 10−3 (n.a.) 1.09 (1.02–1.16) ++++++++ NT5C2 Intragenic
1.11 × 10−8 (3.72 × 10−7) 1.15 (1.10–1.20)
2.91 × 10−8 (5.69 × 10−7) 1.20 (1.13–1.26)
rs548181 11q24.2 125.0 GA 0.88 0.068 (n.a.) 1.04 (0.98–1.11) +++++−+ STT3A 1
8.87 × 10−7 (1.74 × 10−5) 1.11 (1.07–1.16)
1.00 × 10−6 (1.03 × 10−5) 1.10 (1.06–1.14)
rs12966547 18q21.2 50.9 GA 0.58 2.29 × 10−5 (n.a.) 1.08 (1.04–1.12) +−++++++ CCDC68 126
2.60 × 10−10 (5.99 × 10−9) 1.09 (1.06–1.12)
2.35 × 10−8 (4.78 × 10−7) 1.40 (1.28–1.52)
rs17512836 18q21.2 51.3 CT 0.02 0.085 (n.a.) 1.08 (0.96–1.20) −+++++++ TCF4 Intragenic
1.05 × 10−6 (2.86 × 10−5) 1.23 (1.14–1.31)
The SNPs listed are those with a stage 1 P < 5 × 10−8 and/or a combined stage 1 and 2 P < 5 × 10−8. These ten independent (r2 < 0.2) SNPs represent eight physically distinct 
genomic loci, as there are two SNPs listed for two loci (10q24.32-q24.33 and 18q21.2). For the MHC region, only one SNP is listed for clarity. The eight susceptibility loci represent  
three previously reported and five new loci (supplementary table 7). Stage 1 is the discovery GWAS mega-analysis. Stage 2 is the replication sample (single-tailed  
meta-analysis P values are weighted by 1/s.e.), and because the P values are single tailed, some 95% confidence intervals contain 1 (if 0.10 < P < 0.05). Combined values in-
clude stages 1 and 2 (two-tailed meta-analysis P values are weighted by 1/s.e.). For each SNP, P values and odds ratios are listed for stage 1 (top), stage 2 (middle) and combined 
stage 1 and 2 analysis (bottom) with the genomic control (GC)-adjusted values bracketed (n.a., not applicable for stage 2). Alleles are listed with the stage 1 risk allele first; the 
frequency (in stage 1 controls) and odds ratio (OR) refer to the stage 1 risk allele. Bolded P values indicate P < 5 × 10−8, except for in the stage 2 data, where bolded values 
indicate P < 0.05. The directions of association in eight replication samples are represented by + if the associations are in the same direction, − if they are in opposite directions 
and a blank space if the data are not available. Mb is the base position based on hg18. Cytogenetic bands are listed for each SNP, though because only one of multiple MHC SNPs 
are listed, a band range is given in that instance. The nearest gene (or microRNA) is listed, with the distance (kb) from the gene (or if the SNP is intragenic) noted. None of these 
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MIR137 has been implicated in regulating 
adult neurogenesis15,16 and neuronal matura-
tion17, mechanisms through which variation 
at this locus could contribute to brain development abnormalities in 
schizophrenia. Of relevance, two independent schizophrenia imag-
ing studies found MIR137 to be one of three microRNAs with targets 
significantly enriched for association18. In stage 1, SNPs in or near 301 
high-confidence predicted MIR137 targets (with a TargetScan19 prob-
ability of conserved targeting ≥0.9) were enriched for association com-
pared with genes matched for size and marker density: 17 predicted 
MIR137 targets (Supplementary Table 8) had at least one SNP with 
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Figure 1 Manhattan plot for stages 1 and 2. 
Standard −log10 P plot of the study results. 
For the stage 1 results, 16 regions with one or 
more SNP achieving P < 10−6 are highlighted in 
color and labeled with the name of the nearest 
gene. SNPs selected for stage 2 replication are 
highlighted, with the resulting combined P value 
after replication (that is, after incorporation 
of stage 2 results) indicated by the large 
diamonds. Blue highlighting indicates SNPs 
that were less significantly associated after 
replication, and pink highlighting indicates 
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Figure 2 Regional association plots for five new schizophrenia loci. 
Regional P value plots for each of the five new schizophrenia loci:  
1p21.3, 2q32.3, 8p23.2, 8q21.3 and 10q24.32-q24.33. Each plot 
shows the most associated SNP (key SNP) and its genomic region from 
the first column of table 2: stage 1 scan results for each SNP ± 200 kb 
to the key SNP are shown. On the x axis is the genomic position, and on 
the y axis is −log10 P. Larger SNP symbols indicate higher LD (based on 
HapMap 3 data) to the key SNP than smaller SNP symbols. Color coding 
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P < 10−4, which is more than twice as many as the control gene sets (P < 
0.01). Excluding the MHC and MIR137, of the nine loci with genome-
wide significant support either in stage 1 or in the combined set (six loci, 
2q32.3, 8p23.2, 8q21.3, 10q24.32-q24.33, 11q24.2 and 18q21.2; Table 2 
and Supplementary Tables 6,7) or in a joint analysis with bipolar 
disorder (three genes, CACNA1C, ANK3 and ITIH3-ITIH4, described 
below), four genes (TCF4, CACNA1C, CSMD1 and C10orf26) have 
predicted MIR137 target sites according to analyses using three dif-
ferent prediction programs (TargetScan19, PicTar20 and miRanda21). 
In vitro overexpression and locked nucleic acid–mediated knockdown 
of MIR137 in neuronal cell line N2a leads to changes in expression levels 
of TCF4 protein, strongly supporting the prediction that TCF4 is a tar-
get of MIR137 (L.-H. Tsai, personal communication). Our observations 
suggest MIR137-mediated dysregulation as a new etiologic mecha-
nism in schizophrenia.
The International Schizophrenia Consortium (ISC) reported evi-
dence for a polygenic contribution to schizophrenia4. An independent 
family based study confirmed these results, greatly minimizing the 
possibility of population stratification artifact12. We reevaluated the 
polygenic model, dividing stage 1 samples into independent training 
and testing sets (Supplementary Note). The training set had 15,429 
subjects (over twice the size of the ISC training set), and the testing 
set consisted of 6,428 individuals independent of the ISC report. The 
proportion of variance (Nagelkerke’s r2) explained in the testing set 
increased from 3% in the ISC to around 6% here (Supplementary 
Table 9 and Supplementary Fig. 6). This estimate is much lower than 
the true total variation in liability that is tagged by all SNPs because 
SNP effects are estimated with error3,4,22–25. The polygenic model 
appears to explain a substantial fraction of the heritability of schizo-
phrenia4, as has been shown for other complex traits3,26–28. Some of 
these additional risk loci are likely contained near the most highly 
significant results of our stage 1 analysis. Supporting this hypothesis, 
of the top loci that did not reach genome-wide significance in the 
combined stage 1 and 2 analysis, a sign test (P < 10−4) and a Fisher’s 
combined test (P < 10−5) both showed an excess of same-direction 
allelic association (41 of 51 non-MHC SNPs) in the discovery and 
replication datasets.
Clinical, epidemiological and genetic findings suggest shared risk fac-
tors between bipolar disorder and schizophrenia29. In stage 1, three genes 
with strong support had prior genome-wide significant associations with 
bipolar disorder: CACNA1C, the region containing ITIH3-ITIH4 (encod-
ing inter-α (globulin) inhibitors H3 and H4) and ANK3 (encoding ankyrin 
3, node of Ranvier (ankyrin G))10,11,30 (Supplementary Table 10). We 
performed a joint analysis with the Schizophrenia Psychiatric Genome-
Wide Association Study (GWAS) Consortium (PGC) for bipolar disorder 
applying identical analytical methods. After removing duplicate subjects, 
we analyzed 16,374 cases with schizophrenia, schizoaffective disorder or 
bipolar disorder and 14,044 controls. Support for shared susceptibility was 
strengthened (Supplementary Table 11) at CACNA1C (rs4765905, P = 7.0 
× 10−9), ANK3 (rs10994359, P = 2.5 × 10−8) and the ITIH3-ITIH4 region 
(rs2239547, P = 7.8 × 10−9), each of which reached genome-wide signifi-
cance. A coding variant in ITIH4 (p.Pro698Thr; rs4687657) is in perfect 
LD with the most associated SNP. Although we included all subjects from 
an earlier report10, the increased support found with additional independ-
ent cases (N = 11,987) and controls (N = 7,835) provides further evidence 
for shared risk effects of schizophrenia and bipolar disorder.
The risk variants implicated here confer small risks (odds ratios 
~1.10), but the polygenic analysis shows many more susceptibility 
variants with effects for which our sample is underpowered 
(Supplementary Table 12). At every stage where samples were added, 
we found an increase in the number of genome-wide significant loci 
and enhancement of signals at CACNA1C, ANK3 and ITIH3-ITIH4 
when schizophrenia and bipolar disorder were jointly analyzed. Thus, 
gains in power offset any penalty for increased heterogeneity.
In summary, we report seven genome-wide significant schizophrenia 
associations (five of which are new) in a two-stage analysis of 51,695 
individuals. We also report loci that confer susceptibility to both 
bipolar disorder and schizophrenia. The association near MIR137, 
associations in multiple predicted MIR137 targets and the known role 
of MIR137 in neuronal maturation and function together suggest an 
intriguing new insight into the pathogenesis of schizophrenia.





Methods and any associated references are available in the online 
 version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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Overview. Seventeen samples representing 11 countries (Table 1 and 
Supplementary Table 1) comprising all known European-ancestry GWAS 
samples were invited to participate in stage 1. The quality of the clinical data 
was verified by a systematic review of data collection methods and procedures 
at each site (Table 1, Supplementary Table 13 and Supplementary Note).
Quality control. Technical quality control was performed on genotypes gen-
erated for stage 1 by various GWAS platforms (Table 1), with quality control 
conducted separately using a common approach; all datasets were separately 
analyzed (Supplementary Table 3). The SNPs successfully genotyped in each 
study and common to all platforms (N = 11,310) were pruned to remove high 
LD and lower frequency SNPs and were then used for relatedness testing 
in each sample and in the combined total sample. Common quality control 
parameters were applied: (i) missing rate per SNP <0.05 (before sample removal 
below), (ii) missing rate per individual <0.02, (iii) missing rate per SNP <0.02 
(after sample removal above), (iv) missing rate per SNP difference in cases and 
controls <0.02, (v) SNP frequency difference to HapMap <0.15 and (vi) Hardy-
Weinberg equilibrium (controls) P < 10−6. Stage 1 study sample sizes varied 
between 400 and 5,000 individuals (Table 1 and Supplementary Table 3). 
The number of SNPs per study after quality control varied between 250,000 and 
680,000. On average, the quality control processes excluded 15 individuals per 
study (with a range of 0–100 individuals) and 38,000 SNPs per study (with a 
range of 5,000–160,000 SNPs). After quality control, the stage 1 GWAS datasets 
together comprised 21,856 individuals and, for the next steps of the ‘genetic 
quality control’ analysis, a set of 17,074 SNPs common to all platforms and 
successfully genotyped in each stage 1 sample was extracted. These SNPs were 
then further pruned to remove LD (leaving no pairs with r2 > 0.05) and lower 
frequency SNPs (minor allele frequency <0.05), leaving 11,310 SNPs suitable 
for robust relatedness testing and population structure analysis.
Genetic quality control. Genetic quality control included relatedness test-
ing and principal components analyses. Relatedness testing was done with 
PLINK (see URLs), reporting pairs with genome identity (pi-hat) > 0.9 as 
‘identical samples’ and with pi-hat > 0.2 as being closely related. After random 
shuffling, one SNP from each pair was excluded from downstream analysis. 
From groups with multiple related pairs (for example, a family), only one 
individual was kept. After quality control, the PGC GWAS European-ancestry 
sample (stage 1) consisted of 9,394 cases with schizophrenia or schizoaffective 
disorder and 12,462 controls (52% of whom were psychiatrically screened). 
Principal component estimation was done with the same collection of SNPs 
on the non-related subset of individuals. We estimated the first 20 principal 
components and tested each of them for phenotype association (using logistic 
regression with study indicator variables included as covariates) and evalu-
ated their impact on the genome-wide test statistics using λ (the genomic 
control inflation factor based on the median χ2) after genome-wide association 
of the specified principal component. Based on this we decided to include 
principal components 1, 2, 3, 4 and 6 for downstream analysis as associated 
covariates. The deviation noted in Supplementary Figure 1 was observed 
more strongly among SNPs with large numbers of neighboring SNPs in high 
LD (Supplementary Fig. 7); SNPs that tag more variants are more likely to 
capture true genetic effects.
Imputation. Imputation of untyped SNPs was performed within each study 
in batches of 300 individuals. These batches were randomly drawn in order 
to keep the same case-control ratio as in the total sample from that study. We 
used Beagle 3.0.4 (ref. 31). Imputation was performed with CEU+TSI HapMap 
phase 3 data (UCSC hg18/NCBI 36)1 with 410 phased haplotypes encompass-
ing 1,252,901 SNPs. λ was carefully monitored before and after imputation. 
Each of the 17,074 SNPs present on every platform was dropped and reimputed 
with high correlation (Pearson r2 = 0.99973).
Stage 1 association analyses. Stage 1 association analyses of the phenotype 
were performed with the imputed dosages using standard logistic regression, 
which intrinsically properly addresses uncertainly in the imputation results. 
As covariates, we used the study indicator as a categorical variable and five 
principal components derived from the population.
SNPs from the stage 1 association results were grouped into LD regions 
using a simple iterative process after all SNPs in the genome were ranked 
from most to least significant: if a SNP had r2 > 0.2 (defined by Haploview (see 
URLs) analysis of HapMap3 CEU+TSI data) to a more significantly associ-
ated SNP within 1 Mb on either side of it, the SNP was assigned to the region 
defined by the more associated SNP. Distinct regions defined by associated 
variants physically within ±200 kb were tested using a conditional analysis to 
examine the independence of the associations in the PGC schizophrenia data. 
LD regions with P < 2 × 10−5 are reported in Supplementary Table 6 and were 
assessed in independent stage 2 (replication) samples.
Power analysis. The power analysis was performed using the Genetic Power 
Calculator (GPC)32 to calculate the power of the discovery sample (all 17 stage 
1 samples together). Supplementary Table 12 shows the power of this sample 
to detect association at three significance thresholds: a canonical genome-wide 
significance threshold (P < 5 × 10−8), the threshold we used for follow up 
(P < 2 × 10−5) and a more modest threshold of P < 0.001. The middle of these 
is most relevant to the power of this study because this threshold represents a 
level that would have been used to advance to follow up in the larger replication 
study (stage 2) and reported in this manuscript. Presented are power figures 
at representative and relevant odds ratios (ORs) (OR = 1.10, OR = 1.15 and 
OR = 1.20) and allele frequencies (0.05, 0.10, 0.20 and 0.40). Notably, 
although the power of the sample sizes used in this study to identify loci at the 
significance threshold used for follow up at ORs greater than 1.15 was high, 
the power noticeably dropped at an OR of 1.10, where the majority of our 
confirmed findings were made.
Stage 2 association analyses. Stage 2 association analyses were performed 
using all accessible replication European-ancestry samples (stage 2), which 
consisted of 8,442 cases and 21,397 controls (37% of which were screened) in 
19 samples representing 14 countries (Table 1 and Supplementary Table 2). 
We tested the top SNP in each LD region in the replication samples either by 
looking up the data in GWAS datasets not involved in the PGC analysis or by 
focused genotyping in unscanned samples (Supplementary Note). Where new 
genotyping was required, data were provided for the top 15–30 SNPs (depend-
ing on available resources) by collaborators. After receiving P values, ORs, 
standard errors and allele frequencies for the replication datasets, the results 
were aligned, and a standard error–weighted meta-analysis was performed of 
(i) the replication experiment (stage 2) alone and (ii) the combination of the 
PGC discovery and replication data (stages 1 and 2). An analysis of the combi-
nation of stages 1 and 2 was also performed with the genomic control–adjusted 
version of the stage 1 results by converting the genomic control–adjusted 
P value for stage 1 back into an adjusted z score, which was combined with the 
stage 2 meta-analysis result (Table 2).
Conditional analysis. A conditional analysis was performed for all regions 
with P < 10−6 in a logistic regression framework using as covariates the dosages 
of the target SNP of the region, multi-dimensional scaling scores 1–4 and 6 
and the study indicator. Any P < 10−4 was then assumed to be independent 
from the main signal in this region. A plot of these regions after conditioning 
is presented in Supplementary Figure 5. Within a narrow range of ±200 kb 
(which is similar to distances used in the analysis of other phenotypes mani-
festing complex genetics, for example, height3) of the original target SNP, we 
found three regions with a clear sign (permutation-corrected P < 0.05) for one 
or more independent signals (Supplementary Table 5).
Combined analysis of top-associated SNPs with PGC bipolar disorder. 
This combined analysis was performed because after the main analysis of the 
PGC schizophrenia and the PGC bipolar disorder datasets was finalized, we 
noticed several regions associated at high significance levels in both disorder 
groups. We therefore applied the same methods as already described for the 
stage 1 PGC schizophrenia analyses. This included the removal of one indi-
vidual of each overlapping subject pair (see the description of ‘genetic quality 
control’). After creating principal components from the SNPs common to 
each dataset (see ‘genetic quality control’), we tested for association 16,374 
joint cases (cases with schizophrenia, schizoaffective disorder or bipolar dis-
























































20 and the study indicator as covariates (see ‘stage 1 association analyses’). 
We thereafter focused on regions reported by bipolar disorder GWAS. After 
LD pruning, we report in Supplementary Table 11 the three genome-wide 
significant regions.
Additional analyses. Additional analyses performed included an interaction 
analysis (see below and Supplementary Table 14), stage 1 association analyses 
with stricter control for population stratification (Supplementary Figs. 2, 
3,8,9 and Supplementary Note) and a score analysis to test for a polygenic 
model of inheritance (Supplementary Table 9, Supplementary Fig. 6  
and Supplementary Note). An interaction analysis of associated SNPs was 
performed between each pair of loci in Table 2 in a logistic regression model 
that included the main effect of each SNP. No interaction terms were sig-
nificant when correcting for the number of pairs tested (Supplementary 
Table 14). Besides the overall stage 1 quantile-quantile and Manhattan plots 
(Supplementary Figs. 1,4), we present individual stage 1 sample quantile-
quantile and Manhattan plots (Supplementary Figs. 10,11). To comple-
ment the principal component analysis plots for individual stage 1 samples 
(Supplementary Fig. 8), we also present multi-dimensional scaling for all 
stage 1 samples compared to HapMap3 anchors (Supplementary Fig. 12).
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